Congrats @erictopol! An amazing book with profound insights. Highly recommended read!

Some good points by ⁦Joe Grogan 45 Archived⁩ . Biotech is and should continue to be a shining star industry for the U.S. We can maintain our global lead with policies that accelerate innovation reaching patients! statnews.com/2025/05/07/tru…

“If Americans want to maintain our leadership in science and innovation, we need to restore the pact that has always sustained it: that when students devote their lives to discovery that serves all of us, we will stand by them.” statnews.com/2025/05/07/us-…

Go Chicago!!!

👏👏💪💪

Happy Mother’s Day to all moms! Missing mine today!

Interesting IRA change re: orphan drug definition in the reconciliation package just released by House E&C 20 mins ago…

As people chew on MFN this am, it’s worth reminder about other significant US vs. EU healthcare cost differences. Every system different. You cannot simply import foreign prices. If we want to really lower prices for Americans, get rid of OOP costs!

It lowers drug prices for patients, which is what matters here.

Completely agree Adam J. Fein!

It’s “Drug Price Liberation Day!”

Gee, sorry. I’m focused on patients. I’m not shedding a single tear for insurance companies that have the largest skyscrapers in our cities!

Thanks for what you do for patients Rajiv Sivendran! Generally, premiums are paid by “people” not patients per se. Insurance design should have the “well pay for the sick.”

The White House's proposed most favored nation policy is a deeply flawed proposal that would threaten American innovation and patient access.

The solution isn’t price controls. It’s investing in innovation and creating policies that ensure the U.S. remains a global leader in biotech. Read BIO's full statement: bio.org/press-release/…

An outgrowth of the research and writing SUPER AGERS, a book about how we can extend our healthspan by Amy Dockser Marcus gift link wsj.com/health/wellnes…

Trump Admin should support drug makers in launching new drugs at tiered prices for high, middle, and low-income countries and support these actions in Free Trade Agreements so drug makers don't face theft of patents. This policy was pursued in early 2000s, then largely abandoned

Whilst we wait for the results of the inclisiran CVOTs this analysis led by Benoit Arsenault using instrument variables to mimic hepatic and circulating pcsk9 suggests it’s all proportional to atherogenic lipid change #hope track.smtpsendmail.com/9032119/c?p=z3…

U.S. leadership in biotechnology is critical for bringing breakthroughs to patients and our national security. These cuts to research funding are gut punches to our industry’s future! cnn.com/2025/05/13/hea…

Upheaval at FDA pushes some #biotech companies to move early trials out of U.S $XBI $NBI reuters.com/sustainability…